WO1991014700A2 - PROCESS FOR 9α-HYDROXY STEROID DEHYDRATION - Google Patents

PROCESS FOR 9α-HYDROXY STEROID DEHYDRATION Download PDF

Info

Publication number
WO1991014700A2
WO1991014700A2 PCT/US1991/001863 US9101863W WO9114700A2 WO 1991014700 A2 WO1991014700 A2 WO 1991014700A2 US 9101863 W US9101863 W US 9101863W WO 9114700 A2 WO9114700 A2 WO 9114700A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
ioweralkyi
phenyl
defined hereinbefore
acid
Prior art date
Application number
PCT/US1991/001863
Other languages
French (fr)
Other versions
WO1991014700A3 (en
Inventor
Nicholas Carruthers
Sohaila Garshasb
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of WO1991014700A2 publication Critical patent/WO1991014700A2/en
Publication of WO1991014700A3 publication Critical patent/WO1991014700A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16
    • C07J7/0055Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Definitions

  • the 9 ⁇ -hydroxy (OH) steroids are useful intermediates for preparing corticosteroids. Such corticosteroids are useful for treatment of psoriasis, dermatological diseases and inflammation.
  • U.S. Patent 4,127,596 describes a process for dehydrating 9 ⁇ -hydroxysteroid type compounds with a strong acid (pKa less than 1) to give ⁇ 9.II steroids.
  • a ⁇ 9.II steroid is one which possesses a double bond between positions 9 and 11 in the steroid ring.
  • U.S. Patent 4,102,907 and European Patent Application number 87201933.6 teach dehydration of steroid intermediates. John Fried and John A. Edwards, Organic Reactions in Steroid Chemistry, Vol.
  • the present invention is directed towards a process for preparing steroid intermediates of formula (XXX):
  • R1 represents -C ⁇ CR 70 wherein R 70 is hydrogen or Si(CH 3 ) 3 , or R 1 is Ioweralkyi, haloalkyl, phenyl or phenylalkyl, -COR 11 , -COOR 1 wherein R 11 represents hydrogen or Ioweralkyi; or R 1 is -COCH2R 12 wherein R 12 represents hydroxy, halo or alkanoyloxy; R 4 represents H or Ioweralkyi, preferably methyl having either the ⁇ or ⁇ stereochemistry; R9 represents hydrogen, fluoro.
  • R 10 represents hydrogen, phenyl, phenyl substituted with alkyl, halogen, alkoxy, nitro; or R 10 is heteroaryl, alkyl or alkyl substituted with phenyl or halogen.
  • -OCOR 10 at position 17 has the ⁇ -stereochemistry.
  • the present process comprises contacting a 9 ⁇ -hydroxysteroid of the formula (XX):
  • R 1 and R 4 are as defined hereinbefore;
  • Z is a group which can be substituted with the -COR 10 moiety, and
  • R 5 represents Ioweralkyi or R 1 a R R 3 Si- wherein R 1 a , R 2 and R 3 independently represent Ioweralkyi, phenyl or phenylalkyi; and R 9 is as defined hereinbefore;
  • R ⁇ and R 7 independently represent Ioweralkyi or -(CR 20 R 21 ) - and -(CR30R31) W ., respectively, wherein R 20 , R 2 , R30 and R 31 independently represent H, Ioweralkyi, or aryl and w and v independently represent an integer from 0 to 6 and v + w is an integer from 2 to 12, preferably 2, and wherein -(CR 20 R 21 ) V - or -(CR 30 R 31 ) W - are connected together in a ring or through an oxygen or nitrogen atom; and R 9 is as defined hereinbefore;
  • R 6 and R 7 are as defined hereinbefore;
  • R 9 is as defined hereinbefore;
  • the present invention is directed toward a process for preparing novel compounds of the formula:
  • R 1 represents -C ⁇ CR 70 wherein R 70 is hydrogen or -Si(CH 3 ) 3 , or R 1 is Ioweralkyi, haloalkyi, phenyl or phenylalkyi, -COR 11 or -COOR 1 wherein R 11 represents Ioweralkyi, hydroxyaikyi or acyloxy, preferably where Ioweralkyi is methyl, hydroxyaikyi is hydroxymethyl and acyloxy is acetoxy; or -COCH2R 12 wherein R 12 represents hydroxy, halo or alkanoyloxy; R 4 represents H or Ioweralkyi, preferably methyl having either the ⁇ or ⁇ stereochemistry; R 4 represents H or Ioweralkyi, preferably methyl having either the ⁇ or ⁇ stereochemistry; R 9 represents hydrogen, fiuoro, chloro or Ioweralkyi and R 10 represents hydrogen, phenyl, phenyl substituted with alkyl, halogen
  • R and R 4 are as defined hereinbefore;
  • Z is a group which can be substituted with the -COR 10 moiety, and
  • R 5 represents " Ioweralkyi or R 1a R 2 R 3 Si- wherein R 1 a , R 2 and R 3 independently represent Ioweralkyi, phenyl or phenylalkyi; and R 9 is as defined hereinbefore;
  • R 6 and R 7 independently represent Ioweralkyi or -(CR 20 R 21 ) - and -(CR3°R3 1 ) W -, respectively, wherein R 20 , R 21 , R3° and R3 1 independently represent H, Ioweralkyi, or aryl and w and v independently represent an integer from 0 to 6 and v + w is an integer from 2 to 12, preferably 2, and wherein -(CR 0 R 21 ) V - or -(CR 3 °R31) W - are connected together in a ring or through an oxygen or nitrogen atom; and R 9 is as defined hereinbefore;
  • R 6 and R 7 are as defined hereinbefore;
  • R 9 , R 10 and R 12 are as defined hereinbefore, the dotted line represents an optional double bond and the numbering system is illustrated for those preferred compounds.
  • the present process has the unexpected and surprising advantage of regio-specifically dehydrating the 9 ⁇ -OH to form a ⁇ 9,ll steroid possessing the desired R 10 moiety for the production of such steroids in a single step or reaction vessel.
  • the present process also has the advantage of effecting the desired transformation without D-ring rearrangement as described hereinbefore. It is believed that the presence of the 17-ester prevents D-ring homologation (ie. via rearrangement) during the present process. As such, the esterification at position 17 is desirable.
  • the compounds of formulas (XXV) and (XXX) are useful intermediates for the production of corticosteroids from the steroid derived compound 9 ⁇ -hydroxyandrost-4-ene-3,17-dione as described hereinbefore.
  • the present process also has the advantage of providing a one-step process or a simplified two-step process for preparing the compounds of formula (XXX), whose compounds permit convenient substitution of functional groups at positions 9 and 11.
  • the wavy line bond ie. " « ⁇ -" indicates the substituent possesses either the alpha ( ⁇ ) or beta ( ⁇ ) stereochemistry.
  • a substituent possessing the ⁇ stereochemistry lies below the plane of the paper, whereas a substituent possessing the ⁇ " * stereochemistry lies above the plane of the paper, as defined in Leland J. Chinn, Paul D. Klimstra, John S. Baran and Raphael Pappo, The Chemistry and Biochemistry of Steroids, Intra-Science Chemistry Reports, Vol. 3 No. 1 , Intra-Science Research Foundation, Santa Monica, California 1969, pp. 1-82.
  • the " ⁇ " symbol indicates a methyl substituent possessing the ⁇ stereochemistry.
  • alkyl or “loweralkyl”(including the alkyl portion of alkanoyloxy) refers to a straight chain saturated hydrocarbon moiety containing from 1 to 10 carbon atoms, or a branched saturated hydrocarbon moiety of 3 to 10 carbon atoms, such as for example, methyl (ie. -CH3), ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl and the like.
  • phenylalkyi refers to a phenyl moiety convarriably bonded to an alkyl moiety of one to six carbon atoms such as, for example, phenylmethyl, 2-phenylethyl and the like.
  • heteroaryl refers to a cyclic group having at least one O, S and/or N interrupting a carbocyclic ring structure and having a sufficient number of delocalized pi electrons to provide aromatic character, with the heteroaryl group having from 2 to 14, preferably from 2 to 14 carbon atoms, e.g., 2-, 3- or 4-pyridyl, 2- or 3- furyl, 2- or 3-thienyl, 2-, 4- or 5-thiazolyl, 2-, 4- or 5-imidazolyl, 2-, 4- or 5- pyrimidinyl, 2-pyrazinyl, 3- or 4-pyridazinyl, 3-, 5- or 6-[1 ,2,4-triazinyl], 3- or 5-[1 ,2,4-thiadizolyl], 2-, 3- classroom 4-, 5-, 6- or 7-benzofuranyl, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, etc
  • Z can represent hydrogen or any protecting group which is sufficiently labile to permit substitution of the -Z moiety with the -COR 10 moiety under the process conditions.
  • groups include but are not limited to tetrahydropyranyl, alkoxyalkyl, alkoxyalkyl substituted with halogen, oxygen or silicon ie. 2-(trimethylsilyl)ethoxy- methyl and trisubstituted silyl of the formula -SiR 1 a R 2 R 3 wherein R 1 a , R 2 and R 3 independently represents Ioweralkyi, phenyl or phenylalkyi, preferably -Si(CH3)3.
  • R 1 a , R 2 and R 3 independently represents Ioweralkyi, phenyl or phenylalkyi, preferably -Si(CH3)3.
  • Other suitable protecting groups are described in Theodora W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, New York, (19
  • Step (a) of Process (A) the steroid of formula (XXV) is prepared by contacting the compound of formula (XX) with an anhydride, an organic acid, and an acid reagent having a pKa of about 3 or less, preferably 1 or less.
  • Suitable anhydrides are of the formula: (R 10 CO)2 ⁇ wherein R 10 represents hydrogen; phenyl; phenyl substituted with alkyl, halogen, alkoxy or nitro; Ioweralkyi; or Ioweralkyi substituted with phenyl or halogen such as perfluoroalkyl of one to 10 carbon atoms.
  • R 10 is methyl or trifluoromethyl (-CF 3 ).
  • the anhydride is acetic anhydride or trifluoroacetic anhydride ((CF3CO)2 ⁇ ).
  • unsymmetrical anhydrides having differing values for R 10 .
  • the anhydride can be contacted with the compound of formula (XX) in a ratio ranging from excess to about equimola ⁇ l (moles of anhydride: mole compound of formula (XX)), more preferably from about 20 to 5:1 , most preferably about 10 to 1 :1.
  • Suitable organic acids include acids containing from one to 10 carbon atoms. Such acids can be of the formula R 30 COOH (X) wherein R 30 represents Ioweralkyi, preferably ethyl or Ioweralkyi substituted with halogen, preferably fluoro.
  • Representative organic acids include the C-1 to C-10 alkanoic acids such as formic, acetic, propanoic acid, and the like or mixtures thereof, preferably acetic or propanoic.
  • the term "organic acid” does not include the same compounds as does the term "acid reagent".
  • the organic acid can be contacted with the compound of formula (XX) in a ratio ranging from excess to about equimola ⁇ l (moles of organic acid: mole compound of formula (XX)), more preferably from about 100 to 1 , most preferably from about 35 to 1 :1.
  • Suitable acid reagents having a pKa of about 3 or less, preferably about 1 or less include trifluoroacetic acid, para-toluene sulfonic acid, sulfuric acid, perchloric acid, hydrochloric acid, or strong cationic exchange resins possessing sulfonic acid type functionalities, such as described in A.J. Gordon and Richard A. Ford, The Chemist's Companion, A Handbook of Practical Data, Techniques, and References, John Wiley & Sons, New York, New York (1972).
  • the acid reagent can be contacted with the compound of formula (XX) in a ratio ranging from 10 to about 0.1 :1 (moles of acid reagent: mole compound of formula (XX)), more preferably from about 10 to 1 :1.
  • step (a) in process A is carried out in a solvent.
  • suitable solvents include the chlorinated hydrocarbons such as chloroform, dichloromethane, and carbon tetrachloride; and alkane solvents such as hexane or heptane.
  • the amount of solvent can range from an excess amount to an amount sufficient to dissolve the reactants, generally about 10 percent volume basis per reaction mixture.
  • the order of addition of the starting materials ie. reactants, in the present process is not critical. As such, the reactants can be added in any convenient order or together at about the same time.
  • Step (a) can be conducted at ambient pressures and at temperatures ranging from about 0 degrees Celsius (°C) to about 55°C, more preferable from about 0 °C to about 25 °C.
  • the reaction mixture is stirred for a time sufficient to effect the desired completion of the reaction, generally from about 30 minutes to about 24 hours or more.
  • the desired steroids of formula (XXV) thus prepared can be recovered by adding water to the reaction mixture, adjusting the pH to neutrality, ie.
  • a suitable base such as sodium or potasssium hydroxide
  • separating the organic layer containing the desired compound (XXV) from the aqueous layer drying the organic layer over a drying agent such as anhydrous magnesium sulfate (MgSO.4) or sodium sulfate (Na 2 S0 4 ).
  • a drying agent such as anhydrous magnesium sulfate (MgSO.4) or sodium sulfate (Na 2 S0 4 ).
  • MgSO.4 anhydrous magnesium sulfate
  • Na 2 S0 4 sodium sulfate
  • the desired steroid (XXV) can be recovered by conventional procedures, such as evaporation of any solvents present, filtration, crystallization, chromatography, distillation and the like.
  • the desired steroids of formula (XXX) can be prepared by contacting the reaction media from step (a) containing the steroid of formula (XXV) with water, aqueous alkali or aqueous acid under conditions effective to give the desired steroid of formula (XXX).
  • the steroid (XXV) can be separated from the reaction mixture before contacting with " the aqueous media.
  • Suitable alkali sources include bases of alkali and alkaline earth metals including carbonates such as sodium, potassium and cesium carbonates; and hydroxides such as sodium or potassium hydroxides.
  • the aqueous alkali should be sufficient to adjust the pH of the reaction mixture to between about 9-14.
  • Aqueous acid sources include the mineral acids such as hydrochloric, sulfuric, phosphoric and the like.
  • the amount of the aqueous acid should be sufficient to adjust the pH of the reaction mixture to between about about 1-4, preferably less than 2. Where water is employed, an amount of water about equivalent to or greater than the amount of solvent employed can be used.
  • the steroids of formula (XXX) thus prepared can be recovered by separating the organic layer containing the desired compound (XXX) from the aqueous layer, drying the organic layer over a drying agent such as anhydrous magnesium sulfate (MgS04) or sodium sulfate (Na2S0 4 ) using conventional procedures as described hereinbefore to give the desired steroid (XXX).
  • MgS04 anhydrous magnesium sulfate
  • Na2S0 4 sodium sulfate
  • the steroid of formula (XXX) can be prepared by contacting the compound of formula (XX) with an anhydride and a proton acceptor or an acyl halide and a proton acceptor under conditions effective to yield (XXX).
  • Suitable anhydrides are of the formula: (R 10 CO)2 ⁇ wherein R 10 is as defined hereinbefore.
  • R 10 is methyl.
  • unsymmetrical anhydrides having differing values for R 10 .
  • the anhydride can be contacted with the compound of formula (XX) in a ratio ranging from excess to about equimola ⁇ l (moles of anhydride: mole compound of formula (XX)), more preferably from about 50 to 5:1 , most preferably about 40 to 1 :1.
  • Suitable acyl halides are of the formula R 10 CO-X wherein R 10 is as defined hereinbefore and X is halo, preferably chloro.
  • the acyl halide can be contacted with the compound of formula (XX) in a ratio ranging from about excess to about equimola ⁇ l (moles of acyl halide: mole compound of formula (XX)), more preferably from about 40 to 1 :1.
  • Suitable acyl halides include but are not limited to acetyl chloride, propanoyi chloride, trifluoroacetyl chloride, benzoyi chloride, 2-furyl chloride and the like.
  • Suitable proton acceptors are represented by amine bases which include the tertiary amines such as 1 ,5-diazabicyclo[4.3.0]non-5- ene (DBN), 4-N,N-dimethylaminopyridine (DMAP), 1,8- diazobicyclo[5.4.0] undec-7-ene (DBU), 1 ,4-diazabicyclo[2.2.2]octane otherwise known as Dabco or triethylenediamine, dimethylaniline, N,N- dimethyl-n-propylamine, N,N-diethylisopropylamine, N- methylpiperidine, N,N-diethylbutylamine; and heterocyclic nitrogen containing compounds such as morpholine, pyridine, imidazole or mixtures of any of the above.
  • tertiary amines such as 1 ,5-diazabicyclo[4.3.0]non-5- ene (DBN), 4-N
  • the proton acceptor is employed in amounts effective to neutralize acid formed during the reaction.
  • the amine base can be contacted with the compound of formula (XX) in a ratio ranging from about 5 to about equimola ⁇ l (moles of acylating catalyst: mole compound of formula (XX)), more preferably from about 2 to 1.
  • Process (B) can be carried out neat. When carried out neat, excess amounts of any of the reactants ie. the proton acceptor, acyl halide or anhydride, can be used to solubilize the reaction mixture. Where a solvent is employed, suitable solvents include the aromatic hydrocarbons such as benzene, xylenes and toluenes.
  • Process (B) can be conducted at ambient pressures and at temperatures ranging from about ambient to about 150 °C, more preferably from about 80°C to about 105°C.
  • the reaction mixture can be stirred for a time sufficient to effect the desired completion of the reaction, generally from about 30 minutes to about 24 hours or more.
  • the desired steroids of formula (XXX) thus prepared can be recovered by aqueous washings of the organic reaction mixture, followed by washings with brine.
  • the organic layer can be dried over a drying agent such as anhydrous magnesium sulfate (MgS ⁇ 4) or sodium sulfate (Na2S04).
  • MgS ⁇ 4 anhydrous magnesium sulfate
  • Na2S04 sodium sulfate
  • the desired steroid (XXX) can be recovered by conventional procedures as described in Process A.
  • reaction mixture is treated with a few drops of water then poured into water (10 ml) and ethylacetate (10 ml). The organic portion is separated, washed with water and saturated sodium bicarbonate solution, dried over magnesium sulfate and evaporated to give the title compound.
  • the steroids of formula (XX) are known or can be prepared according to known methods such as described in European Patent Application 87201933.6, Patent Publication 0263569 whose preparative teachings are incorporated herein by reference.
  • the steroids of formula (XXi) wherein R1 is -C ⁇ CR 70 are known or can be prepared by contacting a compound of formula (I) with a suitable lithium acetylide compound of the formula LiC ⁇ CR 70 , followed by aqueous or acid hydroloysis to give compound (XXi) as schematically illustrated below:
  • R 4 and R 70 are as defined hereinbefore.
  • the compound of formula (XXii) wherein R 1 is Ioweralkyi, haloalkyl, phenyl or phenylalkyi can be prepared by contacting the compound of formula (I) with the corresponding organometallic reagent ie.
  • organometallic reagent ie. Grignard Reagent or organolithium as taught in J. March, Advanced Organic Chemistry, Reactions, Mechanisms and Structure, Third Edition, John Wiley and Sons, New York, 1985, 1346 pp. as illustrated below:
  • R 1b and R 4 are as defined hereinbefore and M is the metal which can be lithium, magnesium and the like.
  • PREPARATIVE EXAMPLE 2 1 -(21 -bromo-9 ⁇ .17 ⁇ -dihvdroxv-16 ⁇ -methvl-20-oxopregn-4-en-3- . ylidene ⁇ pyrrolidinium bromide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)

Abstract

A process for preparing novel corticosteroid intermediates of formula (XXX) are disclosed. The process entails contacting a 9α-hydroxysteroid of formula (XX) with (A) in step (a) an anhydride, an organic acid and an acid reagent having a pKa of about 3 or less, followed by step (b) treatment with water, aqueous alkali or aqueous acid; or alternatively, with (B) either an anhydride and a proton acceptor or with an acyl halide and a proton acceptor, to give the steroid of formula (XXX). By using step (a) in Proces (A), novel steroid intermediates of formula (XXV) are also obtained.

Description

PROCESS FOR 9α-HYDROXY STEROID DEHYDRATION
BACKGROUND
The 9α-hydroxy (OH) steroids are useful intermediates for preparing corticosteroids. Such corticosteroids are useful for treatment of psoriasis, dermatological diseases and inflammation. U.S. Patent 4,127,596 describes a process for dehydrating 9α-hydroxysteroid type compounds with a strong acid (pKa less than 1) to give Δ9.II steroids. A Δ9.II steroid is one which possesses a double bond between positions 9 and 11 in the steroid ring. U.S. Patent 4,102,907 and European Patent Application number 87201933.6 teach dehydration of steroid intermediates. John Fried and John A. Edwards, Organic Reactions in Steroid Chemistry, Vol. II, Van Nostrand Reinhold Company, New York, New York (1972) pp. 382-385, L F. Fieser and M. Fieser, Steroids, Reinhold Publishing Corporation, New York, (1959) Chapter 18. Homo and Nor Steroids, pp. 577-599 and R.W. Draper and M.S. Puar Carbon- 13 Nuclear Magnetic Resonance Spectra of D-homoannulated 17- hydroxypregnan-20-ones, Steroids 54/1 , July 1989 pp. 1-10 disclose undesirable D-ring homologation via the 17-position by utilizing conventional acidic or alkaline reagents. However, none of these references teaches the concommittant dehydration of 9α-OH to Δ9.II and the formation of a 17-ester from a 9α-hydroxysteroid. It would be desirable to provide a process for preparing Δ9.II steroids possessing the requisite 17-ester moiety from 9α-hydroxysteroid starting materials. The Δ9.II steroids are useful intermediates for the preparation of pharmaceutically active corticosteroids as taught in L. F. Fieser and M. Fieser, Steroids, Chapter 19. Adrenocortical Hormones, pp. 600-726, supra., I. Nitta. and H. Ueno: New Synthesis of Corticoids. Yuki Gosei Kagaku, Vol. 45, No. 5, (1987) pp. 445-461, and in J. Redpath and F.J. Zeelen, in Chem. Soc. Rev., Stereoselective Synthesis of Steroid Side- chains, Vol. 12, (1983), pp. 75-98. Thus, it would be desirable to provide a process for preparing Δ9,ll steroids possessing the requisite 17-ester moiety which avoids D-ring homo-rearrangement and which can also reduce the steps required for their preparation.
SUMMARY
The present invention is directed towards a process for preparing steroid intermediates of formula (XXX):
Figure imgf000004_0001
wherein R1 represents -C≡CR70 wherein R70 is hydrogen or Si(CH3)3, or R1 is Ioweralkyi, haloalkyl, phenyl or phenylalkyl, -COR11, -COOR 1 wherein R11 represents hydrogen or Ioweralkyi; or R1 is -COCH2R12 wherein R12 represents hydroxy, halo or alkanoyloxy; R4 represents H or Ioweralkyi, preferably methyl having either the α or β stereochemistry; R9 represents hydrogen, fluoro. chloro or Ioweralkyi and R10 represents hydrogen, phenyl, phenyl substituted with alkyl, halogen, alkoxy, nitro; or R10 is heteroaryl, alkyl or alkyl substituted with phenyl or halogen. Preferably -OCOR10 at position 17 has the α-stereochemistry. The present process comprises contacting a 9α-hydroxysteroid of the formula (XX):
Figure imgf000005_0001
wherein R1 and R4 are as defined hereinbefore; Z is a group which can be substituted with the -COR10 moiety, and
represents
Figure imgf000005_0002
an enol ether of the formula:
Figure imgf000005_0003
wherein R5 represents Ioweralkyi or R1 a R R3Si- wherein R1 a, R2 and R3 independently represent Ioweralkyi, phenyl or phenylalkyi; and R9 is as defined hereinbefore;
a ketal of the formula
Figure imgf000006_0001
wherein Rδ and R7 independently represent Ioweralkyi or -(CR20R21) - and -(CR30R31)W., respectively, wherein R20, R2 , R30 and R31 independently represent H, Ioweralkyi, or aryl and w and v independently represent an integer from 0 to 6 and v + w is an integer from 2 to 12, preferably 2, and wherein -(CR20R21)V- or -(CR30R31)W- are connected together in a ring or through an oxygen or nitrogen atom; and R9 is as defined hereinbefore;
an enamine of the formula
Figure imgf000006_0002
wherein R6 and R7 are as defined hereinbefore; or
a ketone of the formula
Figure imgf000006_0003
wherein R9 is as defined hereinbefore; with
(A) in step (a) an anhydride of the formula (R10CO)2θ wherein R10 is as defined hereinbefore, an organic acid and an acid reagent having a pKa of about 3 or less, preferably about 1 or less, followed by step (b) treatment with water, aqueous alkali or aqueous acid; or alternatively, with
(B) either an anhydride of the formula (R10Cθ2)O wherein R10 is defined hereinbefore and a proton acceptor or with an acyl halide of the formula R10COX wherein R10 is as defined hereinbefore and X is halogen, preferably chloro and a proton acceptor, to give the steroid (XXX).
In another embodiment, the present invention is directed toward a process for preparing novel compounds of the formula:
Figure imgf000007_0001
wherein R1 represents -C≡CR70 wherein R70 is hydrogen or -Si(CH3)3, or R1 is Ioweralkyi, haloalkyi, phenyl or phenylalkyi, -COR11 or -COOR 1 wherein R11 represents Ioweralkyi, hydroxyaikyi or acyloxy, preferably where Ioweralkyi is methyl, hydroxyaikyi is hydroxymethyl and acyloxy is acetoxy; or -COCH2R12 wherein R12 represents hydroxy, halo or alkanoyloxy; R4 represents H or Ioweralkyi, preferably methyl having either the α or β stereochemistry; R4 represents H or Ioweralkyi, preferably methyl having either the α or β stereochemistry; R9 represents hydrogen, fiuoro, chloro or Ioweralkyi and R10 represents hydrogen, phenyl, phenyl substituted with alkyl, halogen, alkoxy or nitro or R10 is Ioweralkyi or alkyl substituted with phenyl or halogen; comprising contacting a compound of the formula (XX):
Figure imgf000008_0001
wherein R and R4 are as defined hereinbefore; Z is a group which can be substituted with the -COR10 moiety, and
represents
Figure imgf000008_0002
an enol ether of the formula:
Figure imgf000008_0003
wherein R5 represents" Ioweralkyi or R1a R2R3Si- wherein R1 a, R2 and R3 independently represent Ioweralkyi, phenyl or phenylalkyi; and R9 is as defined hereinbefore;
a ketal of the formula
Figure imgf000009_0001
wherein R6 and R7 independently represent Ioweralkyi or -(CR20R21) - and -(CR3°R31)W-, respectively, wherein R20, R21 , R3° and R31 independently represent H, Ioweralkyi, or aryl and w and v independently represent an integer from 0 to 6 and v + w is an integer from 2 to 12, preferably 2, and wherein -(CR 0R21)V- or -(CR3°R31)W- are connected together in a ring or through an oxygen or nitrogen atom; and R9 is as defined hereinbefore;
an enamine of the formula
Figure imgf000009_0002
wherein R6 and R7 are as defined hereinbefore; or
a ketone of the formula
Figure imgf000009_0003
wherein R9 is as defined hereinbefore; with an anhydride of the formula (R 0COJ2θ wherein R10 is as defined hereinbefore, an organic acid and an acid reagent having a pKa of about 3 or less, preferably about 1 or less. This process is the same as step (a) in Process A. The present invention is also directed to novel compound of formula (XXV) useful as intermediates for preparing the compounds of formula (XXX). The present invention is also directed to novel compounds of formula (XXX) as defined hereinbefore.
In another embodiment, the present process gives preferred compounds of formula (XXXi).
Figure imgf000010_0001
wherein R9, R10 and R12 are as defined hereinbefore, the dotted line represents an optional double bond and the numbering system is illustrated for those preferred compounds.
The present process has the unexpected and surprising advantage of regio-specifically dehydrating the 9α-OH to form a Δ9,ll steroid possessing the desired R10 moiety for the production of such steroids in a single step or reaction vessel. The present process also has the advantage of effecting the desired transformation without D-ring rearrangement as described hereinbefore. It is believed that the presence of the 17-ester prevents D-ring homologation (ie. via rearrangement) during the present process. As such, the esterification at position 17 is desirable. The compounds of formulas (XXV) and (XXX) are useful intermediates for the production of corticosteroids from the steroid derived compound 9α-hydroxyandrost-4-ene-3,17-dione as described hereinbefore. The present process also has the advantage of providing a one-step process or a simplified two-step process for preparing the compounds of formula (XXX), whose compounds permit convenient substitution of functional groups at positions 9 and 11.
DETAILED DESCRIPTION OF THE EMBODIMENTS
When utilized in the present specification and in the appended claims the terms listed hereinbelow, unless otherwise indicated are defined as follows:
The wavy line bond, ie. "«~~~-" indicates the substituent possesses either the alpha (α) or beta (β) stereochemistry. A substituent possessing the α stereochemistry lies below the plane of the paper, whereas a substituent possessing the β"*stereochemistry lies above the plane of the paper, as defined in Leland J. Chinn, Paul D. Klimstra, John S. Baran and Raphael Pappo, The Chemistry and Biochemistry of Steroids, Intra-Science Chemistry Reports, Vol. 3 No. 1 , Intra-Science Research Foundation, Santa Monica, California 1969, pp. 1-82. The " ^" symbol indicates a methyl substituent possessing the β stereochemistry.
The dashed line in conjunction with a solid line , ie. " " indicates an optional single or double bond. The term "alkyl" or "loweralkyl"(including the alkyl portion of alkanoyloxy) refers to a straight chain saturated hydrocarbon moiety containing from 1 to 10 carbon atoms, or a branched saturated hydrocarbon moiety of 3 to 10 carbon atoms, such as for example, methyl (ie. -CH3), ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl and the like.
The term "phenylalkyi" refers to a phenyl moiety convaiently bonded to an alkyl moiety of one to six carbon atoms such as, for example, phenylmethyl, 2-phenylethyl and the like. The term "heteroaryl" refers to a cyclic group having at least one O, S and/or N interrupting a carbocyclic ring structure and having a sufficient number of delocalized pi electrons to provide aromatic character, with the heteroaryl group having from 2 to 14, preferably from 2 to 14 carbon atoms, e.g., 2-, 3- or 4-pyridyl, 2- or 3- furyl, 2- or 3-thienyl, 2-, 4- or 5-thiazolyl, 2-, 4- or 5-imidazolyl, 2-, 4- or 5- pyrimidinyl, 2-pyrazinyl, 3- or 4-pyridazinyl, 3-, 5- or 6-[1 ,2,4-triazinyl], 3- or 5-[1 ,2,4-thiadizolyl], 2-, 3-„ 4-, 5-, 6- or 7-benzofuranyl, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, etc. Preferred heteroaryl groups are 2-, 3- or 4-pyridyl, 2- or 3-furyl, 2- or 3-thienyl, 2-, 4- or 5-imidazolyl or 7-indolyl;
The term for "Z" can represent hydrogen or any protecting group which is sufficiently labile to permit substitution of the -Z moiety with the -COR10 moiety under the process conditions. Such groups include but are not limited to tetrahydropyranyl, alkoxyalkyl, alkoxyalkyl substituted with halogen, oxygen or silicon ie. 2-(trimethylsilyl)ethoxy- methyl and trisubstituted silyl of the formula -SiR1 aR2R3 wherein R1 a, R2 and R3 independently represents Ioweralkyi, phenyl or phenylalkyi, preferably -Si(CH3)3. Other suitable protecting groups are described in Theodora W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, New York, (1981) 349 pp.
The processes of the present invention may be schematically illustrated as follows:
Figure imgf000013_0001
proton acceptor
wherein ring A, R1, R4, R9, R10 and Z are as defined hereinbefore. in Step (a) of Process (A), the steroid of formula (XXV) is prepared by contacting the compound of formula (XX) with an anhydride, an organic acid, and an acid reagent having a pKa of about 3 or less, preferably 1 or less. Suitable anhydrides are of the formula: (R10CO)2θ wherein R10 represents hydrogen; phenyl; phenyl substituted with alkyl, halogen, alkoxy or nitro; Ioweralkyi; or Ioweralkyi substituted with phenyl or halogen such as perfluoroalkyl of one to 10 carbon atoms. Preferably R10 is methyl or trifluoromethyl (-CF3). Preferably the anhydride is acetic anhydride or trifluoroacetic anhydride ((CF3CO)2θ). Also contemplated are unsymmetrical anhydrides having differing values for R10. The anhydride can be contacted with the compound of formula (XX) in a ratio ranging from excess to about equimolaπl (moles of anhydride: mole compound of formula (XX)), more preferably from about 20 to 5:1 , most preferably about 10 to 1 :1.
Suitable organic acids include acids containing from one to 10 carbon atoms. Such acids can be of the formula R30COOH (X) wherein R30 represents Ioweralkyi, preferably ethyl or Ioweralkyi substituted with halogen, preferably fluoro. Representative organic acids include the C-1 to C-10 alkanoic acids such as formic, acetic, propanoic acid, and the like or mixtures thereof, preferably acetic or propanoic. For purposes of this invention, the term "organic acid" does not include the same compounds as does the term "acid reagent". The organic acid can be contacted with the compound of formula (XX) in a ratio ranging from excess to about equimolaπl (moles of organic acid: mole compound of formula (XX)), more preferably from about 100 to 1 , most preferably from about 35 to 1 :1.
Suitable acid reagents having a pKa of about 3 or less, preferably about 1 or less include trifluoroacetic acid, para-toluene sulfonic acid, sulfuric acid, perchloric acid, hydrochloric acid, or strong cationic exchange resins possessing sulfonic acid type functionalities, such as described in A.J. Gordon and Richard A. Ford, The Chemist's Companion, A Handbook of Practical Data, Techniques, and References, John Wiley & Sons, New York, New York (1972). The acid reagent can be contacted with the compound of formula (XX) in a ratio ranging from 10 to about 0.1 :1 (moles of acid reagent: mole compound of formula (XX)), more preferably from about 10 to 1 :1.
Optionally and preferably, step (a) in process A is carried out in a solvent. Suitable solvents include the chlorinated hydrocarbons such as chloroform, dichloromethane, and carbon tetrachloride; and alkane solvents such as hexane or heptane. The amount of solvent can range from an excess amount to an amount sufficient to dissolve the reactants, generally about 10 percent volume basis per reaction mixture. In step (a) of Process (A) the order of addition of the starting materials ie. reactants, in the present process is not critical. As such, the reactants can be added in any convenient order or together at about the same time. Step (a) can be conducted at ambient pressures and at temperatures ranging from about 0 degrees Celsius (°C) to about 55°C, more preferable from about 0 °C to about 25 °C. The reaction mixture is stirred for a time sufficient to effect the desired completion of the reaction, generally from about 30 minutes to about 24 hours or more. The desired steroids of formula (XXV) thus prepared can be recovered by adding water to the reaction mixture, adjusting the pH to neutrality, ie. about 7, with a suitable base such as sodium or potasssium hydroxide, separating the organic layer containing the desired compound (XXV) from the aqueous layer, drying the organic layer over a drying agent such as anhydrous magnesium sulfate (MgSO.4) or sodium sulfate (Na2S04). The desired steroid (XXV) can be recovered by conventional procedures, such as evaporation of any solvents present, filtration, crystallization, chromatography, distillation and the like.
In Step (b) of Process (A) the desired steroids of formula (XXX) can be prepared by contacting the reaction media from step (a) containing the steroid of formula (XXV) with water, aqueous alkali or aqueous acid under conditions effective to give the desired steroid of formula (XXX). Alternatively, the steroid (XXV) can be separated from the reaction mixture before contacting with" the aqueous media. Suitable alkali sources include bases of alkali and alkaline earth metals including carbonates such as sodium, potassium and cesium carbonates; and hydroxides such as sodium or potassium hydroxides. The aqueous alkali should be sufficient to adjust the pH of the reaction mixture to between about 9-14. Aqueous acid sources include the mineral acids such as hydrochloric, sulfuric, phosphoric and the like. The amount of the aqueous acid should be sufficient to adjust the pH of the reaction mixture to between about about 1-4, preferably less than 2. Where water is employed, an amount of water about equivalent to or greater than the amount of solvent employed can be used. The steroids of formula (XXX) thus prepared can be recovered by separating the organic layer containing the desired compound (XXX) from the aqueous layer, drying the organic layer over a drying agent such as anhydrous magnesium sulfate (MgS04) or sodium sulfate (Na2S04) using conventional procedures as described hereinbefore to give the desired steroid (XXX).
In alternative Process (B), the steroid of formula (XXX) can be prepared by contacting the compound of formula (XX) with an anhydride and a proton acceptor or an acyl halide and a proton acceptor under conditions effective to yield (XXX). Suitable anhydrides are of the formula: (R10CO)2θ wherein R10 is as defined hereinbefore. Preferably R10 is methyl. Also contemplated are unsymmetrical anhydrides having differing values for R10. The anhydride can be contacted with the compound of formula (XX) in a ratio ranging from excess to about equimolaπl (moles of anhydride: mole compound of formula (XX)), more preferably from about 50 to 5:1 , most preferably about 40 to 1 :1.
Suitable acyl halides are of the formula R10CO-X wherein R10 is as defined hereinbefore and X is halo, preferably chloro. The acyl halide can be contacted with the compound of formula (XX) in a ratio ranging from about excess to about equimolaπl (moles of acyl halide: mole compound of formula (XX)), more preferably from about 40 to 1 :1. Suitable acyl halides include but are not limited to acetyl chloride, propanoyi chloride, trifluoroacetyl chloride, benzoyi chloride, 2-furyl chloride and the like.
Suitable proton acceptors are represented by amine bases which include the tertiary amines such as 1 ,5-diazabicyclo[4.3.0]non-5- ene (DBN), 4-N,N-dimethylaminopyridine (DMAP), 1,8- diazobicyclo[5.4.0] undec-7-ene (DBU), 1 ,4-diazabicyclo[2.2.2]octane otherwise known as Dabco or triethylenediamine, dimethylaniline, N,N- dimethyl-n-propylamine, N,N-diethylisopropylamine, N- methylpiperidine, N,N-diethylbutylamine; and heterocyclic nitrogen containing compounds such as morpholine, pyridine, imidazole or mixtures of any of the above. The proton acceptor is employed in amounts effective to neutralize acid formed during the reaction. The amine base can be contacted with the compound of formula (XX) in a ratio ranging from about 5 to about equimolaπl (moles of acylating catalyst: mole compound of formula (XX)), more preferably from about 2 to 1.
Process (B) can be carried out neat. When carried out neat, excess amounts of any of the reactants ie. the proton acceptor, acyl halide or anhydride, can be used to solubilize the reaction mixture. Where a solvent is employed, suitable solvents include the aromatic hydrocarbons such as benzene, xylenes and toluenes.
Process (B) can be conducted at ambient pressures and at temperatures ranging from about ambient to about 150 °C, more preferably from about 80°C to about 105°C. The reaction mixture can be stirred for a time sufficient to effect the desired completion of the reaction, generally from about 30 minutes to about 24 hours or more. The desired steroids of formula (XXX) thus prepared can be recovered by aqueous washings of the organic reaction mixture, followed by washings with brine. The organic layer can be dried over a drying agent such as anhydrous magnesium sulfate (MgSθ4) or sodium sulfate (Na2S04). The desired steroid (XXX) can be recovered by conventional procedures as described in Process A.
The following examples illustrate various embodiments by which the present invention can be practised, but as such, should not be limited to the overall scope of the same. All temperatures are in degrees Celsius (°C) EXAMPLE 1 Process A: 17α-(AcetvloxvV16β-methvlpregna-4.9π 1 Vdiene-3.20- dione
t
Figure imgf000018_0001
9α, 17α-Dihydroxy-16β-methylpregn-4-ene-3,20-dione (0.54 grams (g) in dichloromethane (5 milliliters) (ml) is added to a cold (ice bath temperature) mixture of para-toluenesulfonic acid monohydrate (0.285 g), acetic acid (2.92 ml) and trifluoroacetic anhydride (2.33 ml) in dichloromethane (5 ml). Upon completion of reaction, as determined by thin layer chromatography (tic), the reaction mixture is treated with water (10 ml), cooled (ice bath temperature) and 20 percent (%)(g/ml basis) sodium hydroxide solution is added until the pH of the solution is 9 to 10. The organic layer is separated, washed with water until the washings are neutral (pH 7), dried over magnesium sulfate and evaporated to give crude product. The title compound is obtained after filtration through a short column of silica gel by eluting with a mixture of ethylacetate and hexane (0.166 g). Nuclear Magnetic Resonance (NMR) (CDCI3), δ ppm 0.59, 1.28, 1.33, 1.92, 2.08, 5.49 and 5.68. EXAMPLE 2 Process A: 17α-21 -BistecetvloxvH 6β-methvlpregna-4.9n 1 diene-
3.20-dione
Figure imgf000019_0001
21 -(Acetyloxy)-9α,17α-dihydroxy-16β-methylpregn-4-ene- 3,20-dione (0.30 g) in dichloromethane (6 ml) is added to a cold (ice bath temperature) mixture of para-toluenesulfonic acid monohydrate (0.137 g), acetic acid (1.4 ml) and trifluoroacetic anydride (1.12 ml) in dichloromethane (9 ml). The reaction mixture is allowed to warm to room temperature and stirred for 4 hours. The reaction mixture is diluted with water (10 ml) and the pH adjusted to 9-10 by addition of 20% sodium hydroxide. The organic layer is separated, washed with water until the washings are neutral (pH 7), dried over magnesium sulfate and evaporated to give the title compound (0.239 g). NMR (CDCI3) δ 0.78, 1.30, 1.38, 2.11 , 2.18, 4.35, 4.81 , 5.52 and 5.73.
EXAMPLE 3 Process A: 17α-(Acetyloxy^-pregna-4.9.11 diene-3.20-dione
Figure imgf000020_0001
A solution of 9α,17α-dihydroxypregn-4-ene-3,20-dione (0.5 g) in dichloromethane is added to a stirred solution of para- toluenesulfonic acid monohydrate (0.266 g), acetic acid (2.7 ml) and trifluoroacetic anhydride (2.2 ml) at 0°. After stirring for 10 minutes the reaction mixture is diluted with dichloromethane (20 ml) and washed with 5% aqueous sodium bicarbonate solution then water. The organic portion is separated, dried over magnesium sulfate and evaporated to give a crude product. The crude material is slurried with diethyl ether and filtered to give the title compound (0.23 g). NMR (CDCI3), δ ppm; 0.627, 1.349, 2.07, 2.10, 5.56 and 5.77 containing about 15% of 17α- acetoxy-9α-hydroxypregn-4-ene-3,20-dione.
EXAMPLE 4 Process A: 17a-21-Bisfacetvloxv prsgna-4. 9M 1 .-diene-3.20-dione
Figure imgf000021_0001
21 -(Acetyloxy)-9α-17α-dihydroxypregn-4-ene-3,20-dione (0.29 g) is added to a stirred solution of βa -toluenesulfonic acid monohydrate (0.133 g), acetic acid (1.35 ml) and acetic anhydride (0.8 ml) at 0°. The reaction mixture is stirred for 1 hour at room temperature, treated with trifluoroacetic anhydride (0.198 ml), stirred for 1 hour and poured into water. The precipitated solid is washed with water and dried in vacuo at 50° to afford the title compound (0.28 α). NMR (CDCI3), δ ppm; 0.709, 1.342, 2.09, 2.17, 4.66, 4.90, 5.56 and 5.76.
EXAMPLE 5 Process A: 17α-21 -Bisfacetvloxv pregna-4. 9(11 Vdiene-3.20-dione
Figure imgf000022_0001
21 -(Acetyloxy)-9α-17α-dihydroxypregn-4-ene-3,20-dιone (0.52 g) is added to a stirred solution of jara-toluenesulfonic acid . monohydrate (0.266 g), acetic acid (2.7 ml) and acetic anhydride (1.6 ml) at 0°. The reaction mixture is stirred at room temperature for 6 hours and then treated with a few drops of concentrated hydrochloric acid to hydrolyze any 3,17α,21-tris (acetyloxy)pregna-3,5,9(11 )-triene-20-one that forms. After stirring for a further 30 minutes the reaction mixture is poured into water. The precipitated solid is washed with water and dried in vacuo at 50° to afford the title compound (0.32 g).
EXAMPLE 6 Process B: 17α-(AcetvloxvV16β-methylpregna-4.9M 1 Vdiene-3.20- dione
Figure imgf000023_0001
9α,17α-Dihydroxy-16β-methylpregn-4-ene-3,20-dione (0.1 g) in acetic anhydride (1 ml) is treated with 4-N,N-dimethylaminopyridine (0.041 g) and heated at 100°. After 12 hours formation of 17α- (acetyloxy)-9α-hydroxy-16β-methylpregn-4-ene-3,20-dione is observed, by thin layer chromatography. The reaction mixture is treated with pyridine (0.5 ml) and 4-N,N-dimethylaminopyridine (0.04 g) and maintained at 100° until complete formation of the title compound is observed. The reaction mixture is treated with a few drops of water then poured into water (10 ml) and ethylacetate (10 ml). The organic portion is separated, washed with water and saturated sodium bicarbonate solution, dried over magnesium sulfate and evaporated to give the title compound.
Preparation of Starting Materials
The steroids of formula (XX) are known or can be prepared according to known methods such as described in European Patent Application 87201933.6, Patent Publication 0263569 whose preparative teachings are incorporated herein by reference.
The steroids of formula (XXi) wherein R1 is -C≡CR70 are known or can be prepared by contacting a compound of formula (I) with a suitable lithium acetylide compound of the formula LiC≡CR70, followed by aqueous or acid hydroloysis to give compound (XXi) as schematically illustrated below:
Figure imgf000024_0001
(I) (XXi)
wherein R4 and R70 are as defined hereinbefore.
The compound of formula (XXii) wherein R1 is Ioweralkyi, haloalkyl, phenyl or phenylalkyi can be prepared by contacting the compound of formula (I) with the corresponding organometallic reagent ie. Grignard Reagent or organolithium as taught in J. March, Advanced Organic Chemistry, Reactions, Mechanisms and Structure, Third Edition, John Wiley and Sons, New York, 1985, 1346 pp. as illustrated below:
Figure imgf000025_0001
wherein R1b and R4 are as defined hereinbefore and M is the metal which can be lithium, magnesium and the like.
The carboxy compound (XXiiϊ) wherein R1 is -COOH and Z is H:
Figure imgf000025_0002
(XXiii)
can be prepared by hydrolyzing the compound of formula (XXiii) wherein Z is H or any other labile group under acidic conditions to give the desired carbonyl compound. PREPARATIVE EXAMPLE 1 9α.17α-Dihvdroxv-16β-methvl-3-(1 -pvrrolidinvnpregna-3.5-diene-20-
Figure imgf000026_0001
9α,17α-Dihydroxy-16β-methylpregn-4-ene-3,20-dione (3.04 g) in methanol (12 ml) is treated with pyrroiidine (0.987 ml) and heated to reflux temperature. The solution momentarily becomes homogeneous, then a precipitate forms. Heating is stopped, the reaction mixture cooled (ice bath temperature) and the precipitate is isolated by filtration and washed with cold methanol. After drying jjn vacuo the title compound (2.86 g) is obtained. NMR (CDCI3), δ ppm; 0.89 1.07, 1.11 , 2.21 , 3.15, 4.78 and 5.09.
PREPARATIVE EXAMPLE 2 1 -(21 -bromo-9α.17α-dihvdroxv-16β-methvl-20-oxopregn-4-en-3- . ylidene^pyrrolidinium bromide
Figure imgf000027_0001
9α,17α-Dihydroxy-16β-methyl-3-(1-pyrrolidinyl)pregna- 3,5-diene-20-one (2.86 g) is added to a stirred solution of HCI (5.0 equivalents) in ethanol. This solution is cooled to -60° and treated with a solution of bromine (1.5 equivalents) in ethanol. Once the addition is complete the reaction mixture is warmed to room temperature and stirred until the bromine color has discharged whereupon the reaction mixture is evaporated to an oil. The oil is redissolved in ethanol and triturated with diethylether to precipitate the title compound (3.28 g) which is isolated by filtration. NMR (CDCI3), δ ppm; 0.73, 1 02, 1.10, 3.89, 4.56 and 6.50.
PREPARATIVE EXAMPLE 3 21 -Bromo-9α.17α-dihvdroxv-16β-methvlpregn-4-ene-3.20-dione
Figure imgf000028_0001
1-(21 -Bromo-9α,17α-dihydroxy-16β-methyl-20-oxopregn- 4-en-3-ylidene)pyrrolidinium bromide (3.2 g) in ethanol (48 ml) is treated with a solution of potassium bicarbonate (2.33 g) in water (48 ml). After stirring at room temperature for 3 hours the reaction mixture is poured into water (80 ml), stirred for 90 minutes and a precipitate is isolated by filtration. The solid is washed with water (100 ml) and dried in vacuo to afford the title compound (1.8 g). NMR (CDCI3), δ ppm; 0.77, 1.06, 1.25, 4.48, 4.62 and 5.69.
PREPARATIVE EXAMPLE 4 21 -f Acetyloxy V9α.17 -dihvdroxy-16β-methvlpregn-4-ene-3.20-dione
Figure imgf000029_0001
21 -Bromo-9α,17α-dihydroxy-16β-methylpregn-4-ene-3,20- dione (0.7 g) in acetone (70 ml) is treated with potassium acetate (3.0 g) and heated at reflux for 5 hours. Evaporation of the solvent gives a solid which is slurried in acetone/water and filtered to give the title compound (0.554 g). NMR (CDCI3), δ ppm; 0.82, 1.12, 1.30, 2.20, 4.95 and 5.88.

Claims

In the Claims;
A process for preparing steroid intermediates of formula
(XXX):
Figure imgf000030_0001
wherein R1 represents -C≡CR70 wherein R70 is hydrogen or Si(CH3)3, or R1 is Ioweralkyi, haloalkyl, phenyl or phenylalkyi, -COR11, -COOR11 wherein R11 represents hydrogen or Ioweralkyi; or R1 is -COCH2R12 wherein R12 represents hydroxy, halo or alkanoyloxy; R4 represents H or Ioweralkyi, preferably methyl having either the α or β stereochemistry; R9 represents hydrogen, fluoro, chloro or Ioweralkyi and R10 represents hydrogen, phenyl, phenyl substituted with alkyl, halogen, alkoxy, nitro; or R10 is heteroaryl, alkyl or alkyl substituted with phenyl or halogen; comprising contacting a 9α-hydroxysteroid of the formula (XX):
Figure imgf000030_0002
wherein R1 and R4 are as defined hereinbefore; Z is a group which can be substituted with the -COR10 moiety, and represents
Figure imgf000031_0001
an enol ether of the formula:
Figure imgf000031_0002
wherein R5 represents Ioweralkyi or R1a R2R3Si- wherein R1 a, R2 and R3 independently represent ioweralkyi, phenyl or phenylalkyi; and R9 is as defined hereinbefore;
a ketal of the formula
Figure imgf000031_0003
wherein R6 and R7 independently represent Ioweralkyi or -(CR20R21)V- and -(CR3°R31)w-, respectively, wherein R20, R21, R30 and R31 independently represent H, Ioweralkyi, or aryl and w and v independently represent an integer from 0 to 6 and v + w is an integer from 2 to 12, preferably 2, and wherein -(CR20R21)V- or -(CR30R3 )W- are connected together in a ring or through an oxygen or nitrogen atom; and R9 is as defined hereinbefore;
an enamine of the formula
Figure imgf000032_0001
wherein R6 and R7 are as defined hereinbefore; or
a ketone of the formula
Figure imgf000032_0002
wherein R9 is as defined hereinbefore; with (A) in step (a) an anhydride of the formula (R10CO)2θ wherein R10 is as defined hereinbefore, an organic acid and an acid reagent having a pKa of about 3 or less, preferably about 1 or less, followed by step (b) treatment with an water, aqueous alkali or aqueous acid; or alternatively, with
(B) either an anhydride of the formula (R10CO2)O wherein R10 is defined hereinbefore and a proton acceptor or with an acyl halide of the formula R10COX wherein R10 is as defined hereinbefore and X is halogen and a proton acceptor, to give the steroid (XXX).
2. The process of claim 1 , wherein the compound of formula '
(XX) is of the formula:
Figure imgf000033_0001
wherein R1 is -COR 1 or -COCH2R12 wherein R1 and R12 are as defined hereinbefore.
3. The process of claim 1 , wherein the compound of formula
(XXV) is of the formula:
Figure imgf000033_0002
wherein R1 is -COR11 or -COCH2R12 wherein R11 and R12 are as defined hereinbefore.
4. The process of claim 1 wherein in process (A), the anhydride is of the formula (R10CO)2θ wherein R10 is Ioweralkyi or perfluoroalkyl of one to 10 carbon atoms and the organic acid is of the formula R3°COOH (X) wherein R30 represents Ioweralkyi.
5. The process of claim 1 wherein in Process (A) the anhydride is acetic anhydride or (CF3CO)2θ, the organic acid is acetic acid or propanoic acid and the acid reagent is para-toluene sulfonic acid.
6. The process of claim 1 wherein in Process (B) the anhydride is acetic anhydride and the proton acceptor is 4-N.N- dimethylaminopyridine.
7, A process for preparing novel compounds of the formula:
Figure imgf000034_0001
wherein R1 represents -C≡CR70 wherein R70 is hydrogen or -Si(CH3)3, or R1 is Ioweralkyi, haloalkyi, phenyl or phenylalkyi, -COR11 or -COOR11 wherein R11 represents Ioweralkyi, hydroxyaikyi or acyloxy, preferably where Ioweralkyi is methyl, hydroxyaikyi is hydroxymethyl and acyloxy is acetoxy; or R1 is -COCH2R12 wherein R12 represents hydroxy, halo or alkanoyloxy; R4 represents H or Ioweralkyi, preferably methyl having either the ά or β stereochemistry; R4 represents H or Ioweralkyi, preferably methyl having either the α or β stereochemistry; R9 represents hydrogen, fluoro, chloro or Ioweralkyi and R10 represents hydrogen, phenyl, phenyl substituted with alkyl, halogen, alkoxy or nitro or R10 is Ioweralkyi or alkyl substituted with phenyl or halogen; comprising contacting a compound of the formula (XX):
Figure imgf000035_0001
wherein R1 and R4 are as defined hereinbefore; Z is a group which can be substituted with the -COR10 moiety, and
represents
Figure imgf000035_0002
an enol ether of the formula:
Figure imgf000035_0003
wherein R5 represents Ioweralkyi or R1a R R3Si- wherein R1 a, R2 and R3 independently represent Ioweralkyi, phenyl or phenylalkyi; and R9 is as defined hereinbefore;
a ketal of the formula
Figure imgf000035_0004
wherein R6 and R7 independently represent Ioweralkyi or -(CR20R21)V- and -(CR30R31)w-, respectively, wherein R20, R21, R30 and R31 independently represent H, Ioweralkyi, or aryl and w and v independently represent an integer from 0 to 6 and v + w is an integer from 2 to 12, preferably 2, and wherein -(CR20R 1)V- or -(CR30R31)W- are connected together in a ring or through an oxygen or nitrogen atom; and R9 is as defined hereinbefore;
an enamine of the formula
Figure imgf000036_0001
wherein R6 and R7 are as defined hereinbefore; or
a ketone of the formula
Figure imgf000036_0002
wherein R9 is as defined hereinbefore; with an anhydride of the formula (R10CO)2θ wherein R10 is as defined hereinbefore,' an organic acid and an acid reagent having a pKa of about 3 or less.
8. The process of claim 7, wherein the compound of formula
(XXX) is of the formula:
Figure imgf000037_0001
wherein R1 is -COR1 1 or -COCH2R12 wherein R1 and R12 are as defined hereinbefore.
9. The process of claim 7 wherein in Process (A) the anhydride is (CF3CO)2θ, the organic acid is acetic acid or propanoic acid, and the acid reagent is para-toluene sulfonic acid.
10. A compound of the formula:
Figure imgf000037_0002
wherein R1 represents -C≡CR70 wherein R70 is hydrogen or -Si(CH3)3, or R1 is Ioweralkyi, haloalkyi, phenyl or phenylalkyi, -COR1 1 or -COOR1 1 wherein R1 1 represents Ioweralkyi, hydroxyaikyi or acyloxy, preferably where Ioweralkyi is methyl, hydroxyaikyi is hydroxymethyl and acyloxy is acetoxy; or -COCH2R12 wherein R12 represents hydroxy, halo or alkanoyloxy; R4 represents H or Ioweralkyi, preferably methyl having either the α or β stereochemistry; R4 represents H or Ioweralkyi, preferably methyl- having either the α or β stereochemistry; R9 represents hydrogen, fluoro, chloro or Ioweralkyi and R10 represents hydrogen, phenyl, phenyl substituted with alkyl, halogen, alkoxy or nitro or R10 is Ioweralkyi or alkyl substituted with phenyl or halogen.
11. The compound of claim 10 of the formula:
Figure imgf000038_0001
12. A compound of the formula:
Figure imgf000038_0002
wherein R1 represents -C≡CR70 wherein R70 is hydrogen or -Si(CH3)3, or R1 is Ioweralkyi, haloalkyi, phenyl or phenylalkyi, -COR11, -COOR11 wherein R11 represents hydrogen or Ioweralkyi; or R1 is -COCH2R12 wherein R12 represents hydroxy, halo or alkanoyloxy; R4 represents H or Ioweralkyi, preferably methyl having either the α or β stereochemistry; R9 represents hydrogen, fluoro, chloro or Ioweralkyi and R10 represents hydrogen, phenyl, phenyl substituted with alkyl, halogen, alkoxy, nitro; or R10 is heteroaryl, alkyl or alkyl substituted with phenyl or halogen.
13. The compound of claim 12 of the formula:
Figure imgf000039_0001
PCT/US1991/001863 1990-03-27 1991-03-25 PROCESS FOR 9α-HYDROXY STEROID DEHYDRATION WO1991014700A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49913690A 1990-03-27 1990-03-27
US499,136 1990-03-27

Publications (2)

Publication Number Publication Date
WO1991014700A2 true WO1991014700A2 (en) 1991-10-03
WO1991014700A3 WO1991014700A3 (en) 1991-11-14

Family

ID=23983984

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/001863 WO1991014700A2 (en) 1990-03-27 1991-03-25 PROCESS FOR 9α-HYDROXY STEROID DEHYDRATION

Country Status (4)

Country Link
EP (1) EP0523132A1 (en)
JP (1) JPH05501115A (en)
AU (1) AU7556291A (en)
WO (1) WO1991014700A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015103A2 (en) * 1992-01-28 1993-08-05 Schering Corporation Novel steroid intermediates and processes for their preparation
CN106946964A (en) * 2017-05-04 2017-07-14 山东赛托生物科技股份有限公司 A kind of preparation method of the steroid nucleus derivative containing double bond

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3546215A (en) * 1967-10-18 1970-12-08 Syntex Corp 6-gem-difluoro steroids
US3780177A (en) * 1967-06-16 1973-12-18 Warner Lambert Co 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
FR2387245A1 (en) * 1977-04-11 1978-11-10 Upjohn Co PROCESS FOR PREPARING A STEROID OF THE ANDROSTA-4,9 (11) -DIENE-3,17-DIONE TYPE
US4154748A (en) * 1978-01-20 1979-05-15 The Upjohn Company Phosphate catalyzed acylation of steroidal tertiary alcohols
EP0263569A2 (en) * 1986-10-10 1988-04-13 Roussel-Uclaf 9-alpha-hydroxysteroids, process for their preparation and process for the preparation of the corresponding 9(11)-dehydro-derivatives.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU75903A1 (en) * 1976-09-29 1978-05-16
GB1416427A (en) * 1972-01-12 1975-12-03 Akzo Nv Alkylated pregnanes and process for obtaining same
GB1478968A (en) * 1973-07-11 1977-07-06 Akzo Nv Alkylated pregnanes
US3980778A (en) * 1973-10-25 1976-09-14 The Upjohn Company Anti-inflammatory steroid
ZA77943B (en) * 1976-03-19 1977-12-28 Upjohn Co Topical steroid clindamycin preparations
US4088537A (en) * 1976-06-21 1978-05-09 The Upjohn Company Δ1 Dehydrogenation of corticoids without side chain degradation by Septomyxa
DE3227312A1 (en) * 1982-07-19 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen NEW 6.16 DIMETHYL CORTICOIDS, THEIR PRODUCTION AND USE
DE3243482A1 (en) * 1982-11-22 1984-05-24 Schering AG, 1000 Berlin und 4709 Bergkamen NEW 6 (ALPHA) METHYL CORTICOIDS, THEIR PRODUCTION AND USE
DE3401680A1 (en) * 1984-01-16 1985-07-18 Schering AG, 1000 Berlin und 4709 Bergkamen 6 (ALPHA), 16SS DIMETHYL CORTICOIDS
DE3434448A1 (en) * 1984-09-17 1986-03-27 Schering AG, 1000 Berlin und 4709 Bergkamen METHOD FOR PRODUCING PREGNAN DERIVATIVES
PT87687B (en) * 1987-06-12 1992-09-30 Gist Brocades Nv PROCESS FOR THE PREPARATION OF 9 (11) -DEHYROID STEROIDS
JPS6471899A (en) * 1987-09-11 1989-03-16 Nippon Zeon Co Steroid compound

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3780177A (en) * 1967-06-16 1973-12-18 Warner Lambert Co 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
US3546215A (en) * 1967-10-18 1970-12-08 Syntex Corp 6-gem-difluoro steroids
FR2387245A1 (en) * 1977-04-11 1978-11-10 Upjohn Co PROCESS FOR PREPARING A STEROID OF THE ANDROSTA-4,9 (11) -DIENE-3,17-DIONE TYPE
US4154748A (en) * 1978-01-20 1979-05-15 The Upjohn Company Phosphate catalyzed acylation of steroidal tertiary alcohols
EP0263569A2 (en) * 1986-10-10 1988-04-13 Roussel-Uclaf 9-alpha-hydroxysteroids, process for their preparation and process for the preparation of the corresponding 9(11)-dehydro-derivatives.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, vol. 94, no. 25, 22 June 1981, (Columbus, Ohio, US); & CZ-A-184220 (J. Moural et al.) 31 August 1978 see page 626 *
Chemical Abstracts, vol. 95, no. 3, 20 July 1981, (Columbus, Ohio, US); 15 August 1980 see page 734 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015103A2 (en) * 1992-01-28 1993-08-05 Schering Corporation Novel steroid intermediates and processes for their preparation
WO1993015103A3 (en) * 1992-01-28 1993-11-25 Schering Corp Novel steroid intermediates and processes for their preparation
CN106946964A (en) * 2017-05-04 2017-07-14 山东赛托生物科技股份有限公司 A kind of preparation method of the steroid nucleus derivative containing double bond

Also Published As

Publication number Publication date
AU7556291A (en) 1991-10-21
WO1991014700A3 (en) 1991-11-14
JPH05501115A (en) 1993-03-04
EP0523132A1 (en) 1993-01-20

Similar Documents

Publication Publication Date Title
US4041055A (en) Process for the preparation of 17α-hydroxyprogesterones and corticoids from androstenes
JP5061061B2 (en) Process for the preparation of the 17-ester of 9α, 21-dihalo-pregnan-11β, 17α-diol-20-one
US4310467A (en) Process and intermediates for the synthesis of vitamin D3 metabolites
US7417140B2 (en) 7α-Hydroxyacetyl and 7α-Hydroperoxyacetyl-substituted steroid compounds
EP1242444A1 (en) Process for preparing 17alpha-acetoxy-11beta- 4-n,n-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates
WO1991014700A2 (en) PROCESS FOR 9α-HYDROXY STEROID DEHYDRATION
JPH0276896A (en) Steroid compound and production thereof
US5248773A (en) 16-methyl-Δ1,4-pregnadiene-3,20-diones
US4451404A (en) 16β-Methyl steroid process
JPH07316184A (en) 3-alkoxy-18-methyl-3,5-estradien-17-one
US4585591A (en) 17β-ethynylsteroids and process for preparing same
JPS6337798B2 (en)
AU636433B2 (en) Process for dehydrating corticosteroid intermediates
US4213912A (en) Process for preparing steroidal [16α,17-d]cyclohexene-21-carboxylic acid esters
US9683010B2 (en) Process for the production of 21-methoxy-11-beta-phenyl-19-nor-pregna-4,9-diene-3,20-dione derivatives
JP2714392B2 (en) Method for producing steroid derivatives
JPS6135999B2 (en)
KR830001132B1 (en) Process for preparing steroidal (16, 17 - b) cyclohexene and naphthaleno - 21 - carboxylic acid and esters
JPS6115878B2 (en)
JPH0361679B2 (en)
JPS6352633B2 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1991907307

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991907307

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1991907307

Country of ref document: EP